Frailty During Cancer Treatment: The Longevity Lever the Metformin Debate Keeps Missing

Most of the longevity conversation this month keeps circling one molecule: metformin. Could a cheap diabetes drug slow aging, or blunt cancer? Reviewing the latest prostate-cancer trials, Peter Attia came away "profoundly unimpressed" by the geroprotector case. A quieter finding landed the same month in the Journal of the National Cancer Institute: among older women treated for breast cancer, those whose frailty worsened during the first year were far more likely to still have a lower quality of life half a decade later.

One story is about a molecule we cannot yet control. The other is about a target most people over 40 can actually move.

What frailty is, and why it is not just "getting old"

Frailty is a measurable loss of physiological reserve, not a vague sense of slowing down. The most widely used definition, the Fried phenotype, counts five signs: weakness (low grip strength), slowness (a gait speed under roughly 0.8 meters per second), self-reported exhaustion, low physical activity, and unintentional weight loss. Three of five and you are classified as frail; one or two, pre-frail.

The distinction matters because reserve is exactly what a serious illness, or its treatment, draws down. A robust body absorbs a course of chemotherapy and recovers. A pre-frail body can tip into frailty and stay there. That transition, not the diagnosis alone, is what the latest data tie to long-term decline.

The established evidence: the transition predicts the decline

The JNCI analysis followed 1,061 women aged 65 and older with non-metastatic breast cancer, drawn from the Women's Health Initiative survivorship cohort. At diagnosis, about two-thirds were robust and one-third pre-frail. Within a year, clinically significant worsening of frailty occurred in 19.5% of them. In fully adjusted models, that worsening tracked with a quality-of-life decline four to six years later (odds ratio 1.48; 95% confidence interval 1.07 to 2.04). In plain terms: it was not being older that predicted a worse life years on. It was losing ground during treatment.

The second established fact is that the frailty phenotype responds to training. In a meta-analysis of resistance-training studies in the American Journal of Preventive Medicine (2022), any resistance training was associated with roughly 15% lower all-cause mortality, with the largest reduction, about 27%, near 60 minutes per week. A large weight-training cohort study in the International Journal of Epidemiology (2024) pointed the same direction for cardiovascular and cancer mortality in older adults. Strength is not a proxy for health here. It is a modifiable input with an outcome attached.

The emerging evidence: can training reverse frailty during treatment?

This is where honesty matters. We have strong data that exercise builds strength and lowers mortality, and growing but softer data that it reverses the frailty phenotype specifically in cancer patients.

The most direct signal comes from a secondary analysis of the GET FIT trial: 386 postmenopausal women (mean age 62), many treated with chemotherapy, completed six months of twice-weekly supervised classes. The strength-training group had significantly higher odds of improving their overall frailty phenotype than a stretching control (odds ratio 1.86), and the women who gained the most were those who started heavier, sicker, and frailer. A separate randomized trial in older postmenopausal breast cancer survivors found that resistance training safely improved upper- and lower-body strength, a direct hit on the "weakness" criterion.

The caution: a 2023 systematic review of prehabilitation programs (25 randomized trials, 2,682 participants) rated the certainty of evidence as very low, and reviewers note there is still no large trial designed with frailty itself as the primary outcome. So the accurate statement is not "exercise reverses frailty in cancer." It is narrower and still worth acting on: training reliably improves the components frailty is built from, and early trials point toward the phenotype itself moving.

Why a pill is the wrong first lever

Set the metformin question beside this. The TAME trial, the serious attempt to test metformin against aging, randomizes 3,000 adults aged 65 to 79 to 1,500 mg per day for four years, and it has not yet returned a verdict. The cancer-adjunct trials Attia reviewed have not shown a silver bullet either. None of that makes metformin useless for its actual indication. It means treating it as your longevity strategy is a bet on evidence that is not in, placed while ignoring an intervention whose evidence already is.

A practical approach, in steps

This is general education, not medical advice. Anyone in active cancer treatment should clear a plan with their oncology team first.

1. Get a baseline before you need one. Measure grip strength (a $25 hand dynamometer), time a 4-meter walk, and count how many times you can stand from a chair in 30 seconds. Write the numbers down.
2. Anchor on resistance training twice a week. Two sessions covering the major movements (a squat or leg press, a hip hinge, a push, a pull, a carry) reach the dose linked to the mortality benefit.
3. Protect protein and body weight. Unintentional weight loss is a frailty criterion; losing muscle is not "slimming down." Keep weight stable and protein intake adequate across the day.
4. Keep moving between sessions. Low activity is its own criterion. A daily walk counters it directly.
5. Re-measure every 8 to 12 weeks. Trends, not single readings, tell you whether reserve is rising or eroding.

Mistakes to avoid

• Waiting until treatment ends. The JNCI data locate the damage in the first year. Reserve lost during treatment is the ground you are trying to hold.
• Confusing cardio with strength. Zone 2 work is valuable, but it does not train grip and leg power, the criteria most tied to frailty. You need both.
• Chasing the supplement or drug first. An NMN order or a metformin script is easier to act on than a squat, which is exactly why it crowds out the thing that works.
• Reading weight loss as success. During illness, unintended loss usually means muscle leaving.
• Training to exhaustion once, then quitting. Two sustainable sessions a week beat one heroic week followed by silence.

A short case

Picture "Marie," 66, pre-frail at a breast cancer diagnosis: grip on the low side, a slightly slow walk, more tired than a year ago. One path is passive: rest through treatment, lose a little strength each month, and land in the 19.5% whose frailty worsens. The other is deliberate: two short strength sessions a week, cleared with her team, protein defended, walks kept up. She may not feel dramatically different at month three, but her chair-stand count holds and her weight is stable. Those held numbers are the outcome.

Markers you can watch

• Grip strength stable or rising
• 30-second chair stands stable or rising
• Gait speed above \~0.8 m/s
• Body weight stable (no unintentional loss over 5%)
• Daily activity maintained through treatment weeks

The takeaway

The metformin debate is worth following, but it is not yours to act on today. Frailty is. Measure your five markers this week, put two resistance sessions on the calendar, and re-check in three months. That is the longevity lever with the evidence already behind it, and it is the one you hold.

Thrive Through Time separates what is established from what is emerging so you can experiment on yourself with your eyes open. We do not sell supplements or protocols.

Sources